TECH is set to report Q2 results on Feb. 4, with EPS seen at 43 cents and revenues at $292M as tariffs, NIH funding and segment shifts shape outlook.
Earlier in 2026, Bio-Techne highlighted its leadership in spatial biology and proteomic analysis under new CEO Kim Kelderman, ...
MINNEAPOLIS, Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming annual ...
Hosted on MSN
What To Expect From Bio-Techne’s (TECH) Q3 Earnings
Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know. Bio-Techne beat analysts’ revenue expectations ...
Shares of Bio-Techne Corp. TECH slid 2.41% to $63.98 Thursday, on what proved to be an all-around mixed trading session for ...
MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling ...
Life sciences company Bio-Techne (NASDAQ:TECH) in Q3 CY2025, with sales falling 1% year on year to $286.6 million. Its non-GAAP profit of $0.42 per share was in line with analysts’ consensus estimates ...
--Bio-Techne Corporation today reported its financial results for the second quarter ending December 31, 2024. "The Bio-Techne team once again executed at a high level and delivered strong second ...
We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...
Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...
Bio-Techne Corp. closed 17.31% short of its 52-week high of $79.28, which the company reached on February 5th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results